Abstract
Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and clinical trials to determine whether agonist replacement therapy is a viable strategy for managing cocaine and/or amphetamine use disorders. The extant literature suggests that agonist replacement therapy may be effective for managing stimulant use disorders, however, the clinical selection of an agonist replacement medication likely needs to be based on the pharmacological mechanism of the medication and the stimulant abused by patients. Specifically, dopamine releasers appear most effective for reducing cocaine use whereas dopamine reuptake inhibitors appear most effective for reducing amphetamine use.
Keywords: Cocaine, methamphetamine, agonist replacement therapy, drug self-administration, clinical trial, dopamine releaser, dopamine reuptake inhibitor.
Current Pharmaceutical Design
Title:Agonist Replacement for Stimulant Dependence: A Review of Clinical Research
Volume: 19 Issue: 40
Author(s): William W. Stoops and Craig R. Rush
Affiliation:
Keywords: Cocaine, methamphetamine, agonist replacement therapy, drug self-administration, clinical trial, dopamine releaser, dopamine reuptake inhibitor.
Abstract: Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and clinical trials to determine whether agonist replacement therapy is a viable strategy for managing cocaine and/or amphetamine use disorders. The extant literature suggests that agonist replacement therapy may be effective for managing stimulant use disorders, however, the clinical selection of an agonist replacement medication likely needs to be based on the pharmacological mechanism of the medication and the stimulant abused by patients. Specifically, dopamine releasers appear most effective for reducing cocaine use whereas dopamine reuptake inhibitors appear most effective for reducing amphetamine use.
Export Options
About this article
Cite this article as:
Stoops W. William and Rush R. Craig, Agonist Replacement for Stimulant Dependence: A Review of Clinical Research, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/138161281940131209142843
DOI https://dx.doi.org/10.2174/138161281940131209142843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Action of Anti-HIV Drugs and Resistance: Reverse Transcriptase Inhibitors and Protease Inhibitors
Current Pharmaceutical Design Biological Roles of the Eclectic Chromogranin-A-derived Peptide Catestatin
Current Medicinal Chemistry Yeast Network and Report of New Stochastic-Credibility Cell Cycle Models
Current Bioinformatics Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion
Current Pharmaceutical Design In Vitro Synergistic Anti-yeast Activity between Galloyl Derivatives and Amphotericin B
The Natural Products Journal Patent Selections:
Recent Patents on Biomarkers New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Discovery of Novel Genes Mediating Glucose and Lipid Metabolisms
Current Protein & Peptide Science Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Editorial (Thematic Issue: Rheumatic Diseases as the Fuel to Inflamm-aging)
Current Aging Science Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Current Topics in Medicinal Chemistry Mechanisms and Drug Targets for Pancreatic Cancer Chemoprevention
Current Medicinal Chemistry Pharmacogenetic Analysis of SNPs in Genes Involved in the Pharmacokinetics and Response to Lopinavir/Ritonavir Therapy
Current Drug Metabolism Current Research on Opioid Receptor Function
Current Drug Targets Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery